Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BIOVF NASDAQ:BMRN OTCMKTS:BVNRY NYSE:QGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIOVFSwedish Orphan Biovitrum$30.56$29.60$25.80▼$32.25$10.88B0.4546 shsN/ABMRNBioMarin Pharmaceutical$59.39+0.5%$57.94$52.93▼$92.05$11.41B0.351.91 million shs152,675 shsBVNRYBavarian Nordic$12.26-0.5%$10.97$6.60▼$12.98$2.90B1.35,822 shs659 shsQGENQiagen$46.64-0.6%$48.70$37.63▼$51.88$10.35B0.641.39 million shs194,125 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIOVFSwedish Orphan Biovitrum0.00%-0.62%+2.58%+0.89%-2.30%BMRNBioMarin Pharmaceutical+1.41%+2.85%+1.63%+5.31%-35.22%BVNRYBavarian Nordic-0.48%-0.88%+0.71%+33.80%-6.73%QGENQiagen+0.87%-3.99%-5.94%+2.62%+5.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIOVFSwedish Orphan BiovitrumN/AN/AN/AN/AN/AN/AN/AN/ABMRNBioMarin Pharmaceutical4.9978 of 5 stars4.44.00.03.34.11.74.4BVNRYBavarian NordicN/AN/AN/AN/AN/AN/AN/AN/AQGENQiagen4.1877 of 5 stars1.14.01.74.52.81.72.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIOVFSwedish Orphan Biovitrum 4.00Strong BuyN/AN/ABMRNBioMarin Pharmaceutical 2.72Moderate Buy$93.4357.34% UpsideBVNRYBavarian Nordic 0.00N/AN/AN/AQGENQiagen 2.27Hold$49.696.52% UpsideCurrent Analyst Ratings BreakdownLatest BVNRY, BMRN, BIOVF, and QGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025BMRNBioMarin PharmaceuticalRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$85.008/13/2025BMRNBioMarin PharmaceuticalZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/7/2025QGENQiagenCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold8/7/2025QGENQiagenUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$48.00 ➝ $50.008/6/2025BMRNBioMarin PharmaceuticalGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$101.00 ➝ $106.008/5/2025BMRNBioMarin PharmaceuticalWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$94.008/5/2025BMRNBioMarin PharmaceuticalUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$113.00 ➝ $114.007/22/2025BMRNBioMarin PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$97.00 ➝ $96.007/15/2025BMRNBioMarin PharmaceuticalWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$95.007/14/2025BMRNBioMarin PharmaceuticalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$108.00 ➝ $113.007/3/2025BMRNBioMarin PharmaceuticalMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$97.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIOVFSwedish Orphan Biovitrum$2.46B4.42$2.05 per share14.90$11.36 per share2.69BMRNBioMarin Pharmaceutical$2.85B4.00$3.31 per share17.95$31.39 per share1.89BVNRYBavarian Nordic$829.12M3.50$1.01 per share12.16$6.99 per share1.75QGENQiagen$1.98B5.24$3.21 per share14.51$15.77 per share2.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIOVFSwedish Orphan Biovitrum$367.52M$1.1925.68∞N/A16.05%11.67%6.34%10/23/2025 (Estimated)BMRNBioMarin Pharmaceutical$426.86M$3.3717.6413.620.7421.45%12.59%10.13%11/4/2025 (Estimated)BVNRYBavarian Nordic$143.26M$0.8714.0911.67N/A21.95%12.75%10.23%11/14/2025 (Estimated)QGENQiagen$83.59M$1.6927.5218.962.5718.30%14.77%8.87%11/5/2025 (Estimated)Latest BVNRY, BMRN, BIOVF, and QGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/22/2025Q2 2025BVNRYBavarian NordicN/A$0.23N/A$0.23N/A$251.14 million8/5/2025Q2 2025QGENQiagen$0.60$0.60N/A$0.44$523.97 million$533.54 million7/16/2025Q2 2025BIOVFSwedish Orphan Biovitrum$0.18$0.24+$0.06$0.19$644.68 million$649.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIOVFSwedish Orphan BiovitrumN/AN/AN/AN/AN/ABMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/ABVNRYBavarian NordicN/AN/AN/AN/AN/AQGENQiagen$0.250.54%N/A14.79%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIOVFSwedish Orphan Biovitrum0.221.000.66BMRNBioMarin Pharmaceutical0.105.563.60BVNRYBavarian NordicN/A2.811.44QGENQiagen0.251.611.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIOVFSwedish Orphan BiovitrumN/ABMRNBioMarin Pharmaceutical98.71%BVNRYBavarian NordicN/AQGENQiagen70.00%Insider OwnershipCompanyInsider OwnershipBIOVFSwedish Orphan BiovitrumN/ABMRNBioMarin Pharmaceutical0.85%BVNRYBavarian NordicN/AQGENQiagen9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIOVFSwedish Orphan Biovitrum1,937356.00 millionN/ANot OptionableBMRNBioMarin Pharmaceutical3,040192.01 million190.38 millionOptionableBVNRYBavarian Nordic1,611236.57 millionN/ANot OptionableQGENQiagen5,765222.29 million202.29 millionOptionableBVNRY, BMRN, BIOVF, and QGEN HeadlinesRecent News About These CompaniesQIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise1 hour ago | zacks.comQiagen N.V. $QGEN Shares Bought by Graham Capital Management L.P.4 hours ago | marketbeat.comQiagen N.V. $QGEN Shares Sold by BNP Paribas Financial MarketsSeptember 3 at 4:47 AM | marketbeat.comState of Wyoming Purchases 9,987 Shares of Qiagen N.V. $QGENSeptember 2 at 5:43 AM | marketbeat.comRaymond James Financial Inc. Has $8.93 Million Position in Qiagen N.V. $QGENSeptember 2 at 3:50 AM | marketbeat.comHighTower Advisors LLC Sells 7,805 Shares of Qiagen N.V. $QGENSeptember 2 at 3:32 AM | marketbeat.comQIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic TestingSeptember 2 at 2:30 AM | businesswire.comQiagen grabbed 'opportunistic window' to sell $750m CBSeptember 1 at 5:58 PM | globalcapital.comGCharles Schwab Investment Management Inc. Lowers Stock Position in Qiagen N.V. $QGENSeptember 1 at 3:11 AM | marketbeat.comZacks Research Analysts Lift Earnings Estimates for QiagenAugust 31 at 5:38 AM | marketbeat.comQIAGEN N.V. $QGEN Shares Sold by Northern Trust CorpAugust 30, 2025 | marketbeat.comZacks Research Comments on QIAGEN's Q3 Earnings (NYSE:QGEN)August 30, 2025 | americanbankingnews.comQiagen N.V. $QGEN Shares Sold by Earnest Partners LLCAugust 29, 2025 | marketbeat.comQIAGEN N.V. Announces Conversion Price of New Net Share Settled Convertible BondsAugust 28, 2025 | businesswire.comQIAGEN N.V. Announces Successful Placement of New Net Share Settled Convertible BondsAugust 28, 2025 | businesswire.comQIAGEN N.V. $QGEN Holdings Trimmed by Hsbc Holdings PLCAugust 28, 2025 | marketbeat.comQIAGEN N.V. Launches Non-US Offering of Net Share Settled Convertible BondsAugust 28, 2025 | businesswire.comQIAGEN N.V. $QGEN Shares Acquired by Price T Rowe Associates Inc. MDAugust 27, 2025 | marketbeat.comQiagen Announces Major BlackRock ShareholdingAugust 26, 2025 | msn.comQiagen Receives Notification of BlackRock’s Significant StakeAugust 26, 2025 | msn.comOak Harvest Investment Services Invests $3.19 Million in Qiagen N.V. $QGENAugust 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBVNRY, BMRN, BIOVF, and QGEN Company DescriptionsSwedish Orphan Biovitrum OTCMKTS:BIOVF$30.56 0.00 (0.00%) As of 09/2/2025Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.BioMarin Pharmaceutical NASDAQ:BMRN$59.38 +0.30 (+0.50%) As of 10:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Bavarian Nordic OTCMKTS:BVNRY$12.26 -0.06 (-0.48%) As of 09/2/2025 03:31 PM EasternBavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.Qiagen NYSE:QGEN$46.64 -0.28 (-0.59%) As of 10:22 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers Tesla Bulls Need to Tread Very Carefully Right Now Amazon Faces Rare Downgrade—Is the Rally at Risk? What to Watch for From D-Wave Now That Earnings Are Done Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
